The Canadian Pediatric Society recommends eligible children be vaccinated. Fewer infections means less chance of dangerous variants. Each person infected with COVID-19 provides a chance for the virus to mutate and become more resistant to treatments or vaccines. Children can spread the virus even if they don't have symptoms, potentially putting vulnerable friends, family or community members at risk. Most cases in children are mild, but some kids can get very sick, have long-lasting symptoms (Long COVID), or complications such as multisystem inflammatory syndrome in children (MIS-C). Results are expected in late spring 2022. Routine school immunizations can continue as scheduled. Children are recommended to wait at least 14 days between the COVID-19 vaccine and the seasonal flu vaccine. Serious side effects from the vaccine are rare Estimates for Omicron are not available at this time. Nearly 88% effective in preventing illness due to Delta. The children's dose is 1/2 the amount of the regular vaccine (50 mcg per dose instead of 100 mcg). Moderna vaccine is available to children 6 to 11. Two doses are 74% effective at preventing hospitalization due to Delta or Omicron and no serious side effects were identified. The children's dose is 1/3 the amount of the regular vaccine (10 mcg per dose instead of 30 mcg). Pfizer vaccine is approved for children 5 to 11. Pfizer or Moderna: Call 811 or visit a participating pharmacy. Pfizer: Book online (AHS clinic or pharmacy). Minors under 18 require verbal or written consent from a parent or guardian to be vaccinated. When to book: Must wait at least 5 months after third dose.Īll vaccines approved for children require 2 doses at least 8 weeks apart to be fully protected. Eligibility: Albertans 12 and older with eligible immunocompromising conditions. #United federation papers please passport back how to
How to book: Call 811 or book online (pharmacy or AHS clinic).
When to book: Recommended to wait 28 days between the first and second dose, and 8 weeks between the second and third dose.Eligibility: Albertans 5 and older with eligible immunocompromising conditions.Individuals taking certain medications for autoimmune diseases including rituximab, ocrelizumab, ofatumumab and methotrexate.Recipients of active cancer treatment (chemotherapy, immunotherapy or targeted therapies), excluding those receiving only hormonal therapy, radiation therapy or surgery.Individuals with chronic kidney disease receiving regular dialysis.Transplant recipients, including solid organ and hematopoietic stem cell transplants.Recipients of immunosuppressive therapies (for example, anti-B cell therapies, high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents).Individuals with advanced untreated HIV infection or acquired immunodeficiency syndrome (AIDS).Individuals with moderate to severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome).Recipients of chimeric antigen receptor (CAR)-T-cell therapy.Individuals with certain immunocompromising conditions should receive 3 doses followed by a fourth dose to provide stronger protection because their immune systems respond differently to vaccines than other people without these conditions.
0 kommentar(er)
